<p>Agios 製藥（NASDAQ:AGIO - 獲取免費報告）在週四發佈的一份報告中，將其目標價格從 62.00 美元上調至 65.00 美元，HC Wainwright 報道。該券商目前對這家生物製藥公司的股票給予 “買入” 評級。HC Wainwright 的目標價格意味着與該公司之前收盤價相比，潛在上漲幅度為 129.02%。</p>
<p>獲取 <strong>Agios 製藥</strong> 的提醒：</p>
<p>其他一些股票研究分析師也最近對 AGIO 發表了評論。高盛集團在 11 月 20 日的研究報告中將 Agios 製藥的股票目標價格從 40.00 美元下調至 25.00 美元，並對該股票給予 “中性” 評級。Leerink Partners 在 12 月 26 日的報告中將 Agios 製藥的股票目標價格從 34.00 美元上調至 40.00 美元，並給予該股票 “跑贏大盤” 評級。摩根大通在 1 月 6 日的研究報告中將 Agios 製藥的股票目標價格從 20.00 美元上調至 25.00 美元，並給予該股票 “中性” 評級。美國銀行在 12 月 24 日的研究報告中將 Agios 製藥的目標價格從 32.00 美元上調至 34.00 美元，並給予該公司 “買入” 評級。最後，Truist Financial 在 12 月 24 日的報告中將 Agios 製藥的目標價格從 32.00 美元上調至 38.00 美元，並給予該股票 “買入” 評級。六位股票研究分析師對該股票給予 “買入” 評級，四位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “持有”，平均目標價格為 39.78 美元。</p>
<p><strong>獲取我們對 Agios 製藥的最新股票分析</strong></p>
<h2>Agios 製藥股票上漲 2.4%</h2>
<p>NASDAQ:AGIO 的股票在週四交易中上漲 0.67 美元，達到 28.38 美元。該股票的交易量為 471,346 股，而其平均交易量為 925,984 股。Agios 製藥的 12 個月低點為 22.24 美元，12 個月高點為 46.00 美元。該股票的 50 日簡單移動平均線為 27.37 美元，200 日簡單移動平均線為 34.17 美元。該股票的市值為 16.5 億美元，市盈率為-4.05，貝塔值為 0.91。</p>
<p>Agios 製藥（NASDAQ:AGIO - 獲取免費報告）最近於 2 月 12 日發佈了季度財報。這家生物製藥公司報告本季度每股收益為（1.85 美元），超出市場共識預期的（1.96 美元）0.11 美元。該季度的營業收入為 1997 萬美元，而市場共識預期為 1206 萬美元。Agios 製藥的淨利潤率為-895.86%，股本回報率為-28.35%。該公司的季度收入同比增長 86.9%。整體來看，賣方分析師預測 Agios 製藥在當前年度的每股收益將為-6.85 美元。</p>
<h2>內部買賣</h2>
<p>在其他新聞中，內部人士 Sarah Gheuens 於 12 月 30 日出售了 2932 股該公司的股票。股票以平均價格 27.09 美元出售，總價值為 79427.88 美元。交易完成後，該內部人士直接持有 64895 股公司股票，價值約為 1755296.55 美元。此交易代表其持股比例減少了 4.33%。該交易在向 SEC 提交的文件中披露，文件可在此鏈接查看。此外，內部人士 James William Burns 於 12 月 30 日出售了 2932 股該公司的股票。股票以平均價格 27.09 美元出售，總交易額為 79427.88 美元。交易完成後，該內部人士直接持有 31718 股公司股票，價值 859240.62 美元。此交易代表其持股比例減少了 8.46%。該銷售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士共出售了價值 901977 美元的 33303 股公司股票。公司內部人士持有公司股票的 4.30%。</p>
<h2>Agios 製藥的機構交易</h2>
<p>一些對沖基金和其他機構投資者最近修改了對該股票的持有。AlphaCentric Advisors LLC 在第四季度購買了 Agios 製藥的新頭寸，價值 358,000 美元。紐約州共同退休基金在第四季度將其在 Agios 製藥的股份增加了 3.9%。紐約州共同退休基金現在持有 51707 股生物製藥公司的股票，價值 1407000 美元，此前在該期間內又購買了 1917 股。Campbell &amp; CO 投資顧問 LLC 在第四季度購買了 Agios 製藥的新股份，價值約 224,000 美元。Knott David M Jr 在第四季度獲得了 Agios 製藥的新頭寸，價值約 490,000 美元。最後，Alps Advisors Inc.在第四季度將其在 Agios 製藥的持股增加了 73.8%。Alps Advisors Inc.現在持有 47881 股生物製藥公司的股票，價值 1303000 美元，此前在上個季度又購買了 20327 股。</p>
<h2>關於 Agios 製藥</h2>
<p>（獲取免費報告）</p>
<p>Agios 製藥公司成立於 2008 年，是從 Dana-Farber 癌症研究所和 Broad Institute 的研究中分拆出來的生物製藥公司。總部位於馬薩諸塞州劍橋，Agios 專注於理解和針對細胞代謝，以開發用於癌症和罕見遺傳疾病的新療法。該公司的科學平台整合了基因組發現、代謝分析和精準醫學方法，以識別和推進能夠糾正或利用代謝功能障礙的小分子候選藥物。</p>
<p>Agios 的主要產品是針對特定癌症突變的 IDH（異檸檬酸脱氫酶）抑制劑。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Agios Pharmaceuticals</li>
<li>USAU：投資者無法忽視的美國黃金 - 銅故事。</li>
<li>國防部剛剛獲得了一家新的無人機供應商</li>
<li>認為你錯過了白銀？你錯了。原因在這裏。</li>
<li>何時購買黃金（從數學角度）</li>
<li>特朗普的人工智能秘密：比 Nvidia 快 100 倍</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdJTw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Agios Pharmaceuticals 嗎？</h2>
<p>在你考慮 Agios Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Agios Pharmaceuticals 並不在名單上。</p>
<p>雖然 Agios Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Agios制藥

<p>HC Wainwright 將 Agios Pharmaceuticals (NASDAQ:AGIO) 的目標價格從 62.00 美元上調至 65.00 美元，維持 “買入” 評級。這個新目標暗示相較於前一交易日收盤價有 129.02% 的潛在上漲空間。其他分析師的看法各異，高盛將其目標下調至 25.00 美元，並維持 “中性” 評級，而其他分析師則設定了更高的目標。Agios 的股價上漲 2.4%，至 28.38 美元，市值為 16.5 億美元。該公司報告的季度每股收益為（1.85 美元），超出預期，收入為 1997 萬美元，同比增長 86.9%</p>

<p>Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) had its price objective hoisted by HC Wainwright from $62.00 to $65.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a &#34;buy&#34; rating on the biopharmaceutical company's stock. HC Wainwright's price objective would indicate a potential upside of 129.02% from the company's previous close.</p>
<div class="lb-trans"><p>Agios 製藥（NASDAQ:AGIO - 獲取免費報告）在週四發佈的一份報告中，將其目標價格從 62.00 美元上調至 65.00 美元，HC Wainwright 報道。該券商目前對這家生物製藥公司的股票給予 “買入” 評級。HC Wainwright 的目標價格意味着與該公司之前收盤價相比，潛在上漲幅度為 129.02%。</p>
</div><p>Get <strong>Agios Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Agios 製藥</strong> 的提醒：</p>
</div><p>A number of other equities research analysts have also recently commented on AGIO. The Goldman Sachs Group dropped their price objective on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a &#34;neutral&#34; rating on the stock in a research note on Thursday, November 20th. Leerink Partners increased their price target on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, December 26th. JPMorgan Chase &amp; Co. upped their price objective on shares of Agios Pharmaceuticals from $20.00 to $25.00 and gave the stock a &#34;neutral&#34; rating in a research report on Tuesday, January 6th. Bank of America raised their target price on Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, December 24th. Finally, Truist Financial upped their price target on Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, December 24th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of &#34;Hold&#34; and an average price target of $39.78.</p>
<div class="lb-trans"><p>其他一些股票研究分析師也最近對 AGIO 發表了評論。高盛集團在 11 月 20 日的研究報告中將 Agios 製藥的股票目標價格從 40.00 美元下調至 25.00 美元，並對該股票給予 “中性” 評級。Leerink Partners 在 12 月 26 日的報告中將 Agios 製藥的股票目標價格從 34.00 美元上調至 40.00 美元，並給予該股票 “跑贏大盤” 評級。摩根大通在 1 月 6 日的研究報告中將 Agios 製藥的股票目標價格從 20.00 美元上調至 25.00 美元，並給予該股票 “中性” 評級。美國銀行在 12 月 24 日的研究報告中將 Agios 製藥的目標價格從 32.00 美元上調至 34.00 美元，並給予該公司 “買入” 評級。最後，Truist Financial 在 12 月 24 日的報告中將 Agios 製藥的目標價格從 32.00 美元上調至 38.00 美元，並給予該股票 “買入” 評級。六位股票研究分析師對該股票給予 “買入” 評級，四位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “持有”，平均目標價格為 39.78 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Agios Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Agios 製藥的最新股票分析</strong></p>
</div><h2>Agios Pharmaceuticals Stock Up 2.4%</h2>
<div class="lb-trans"><h2>Agios 製藥股票上漲 2.4%</h2>
</div><p>Shares of NASDAQ:AGIO traded up $0.67 during trading on Thursday, hitting $28.38. The stock had a trading volume of 471,346 shares, compared to its average volume of 925,984. Agios Pharmaceuticals has a 12-month low of $22.24 and a 12-month high of $46.00. The stock has a 50-day simple moving average of $27.37 and a two-hundred day simple moving average of $34.17. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -4.05 and a beta of 0.91.</p>
<div class="lb-trans"><p>NASDAQ:AGIO 的股票在週四交易中上漲 0.67 美元，達到 28.38 美元。該股票的交易量為 471,346 股，而其平均交易量為 925,984 股。Agios 製藥的 12 個月低點為 22.24 美元，12 個月高點為 46.00 美元。該股票的 50 日簡單移動平均線為 27.37 美元，200 日簡單移動平均線為 34.17 美元。該股票的市值為 16.5 億美元，市盈率為-4.05，貝塔值為 0.91。</p>
</div><p>Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.85) EPS for the quarter, beating the consensus estimate of ($1.96) by $0.11. The business had revenue of $19.97 million for the quarter, compared to the consensus estimate of $12.06 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The firm's revenue for the quarter was up 86.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Agios Pharmaceuticals will post -6.85 earnings per share for the current year.</p>
<div class="lb-trans"><p>Agios 製藥（NASDAQ:AGIO - 獲取免費報告）最近於 2 月 12 日發佈了季度財報。這家生物製藥公司報告本季度每股收益為（1.85 美元），超出市場共識預期的（1.96 美元）0.11 美元。該季度的營業收入為 1997 萬美元，而市場共識預期為 1206 萬美元。Agios 製藥的淨利潤率為-895.86%，股本回報率為-28.35%。該公司的季度收入同比增長 86.9%。整體來看，賣方分析師預測 Agios 製藥在當前年度的每股收益將為-6.85 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In other news, insider Sarah Gheuens sold 2,932 shares of the firm's stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $79,427.88. Following the transaction, the insider directly owned 64,795 shares of the company's stock, valued at approximately $1,755,296.55. This trade represents a 4.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider James William Burns sold 2,932 shares of the firm's stock in a transaction that occurred on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the transaction, the insider directly owned 31,718 shares in the company, valued at $859,240.62. This trade represents a 8.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 33,303 shares of company stock worth $901,977 in the last ninety days. Company insiders own 4.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Sarah Gheuens 於 12 月 30 日出售了 2932 股該公司的股票。股票以平均價格 27.09 美元出售，總價值為 79427.88 美元。交易完成後，該內部人士直接持有 64895 股公司股票，價值約為 1755296.55 美元。此交易代表其持股比例減少了 4.33%。該交易在向 SEC 提交的文件中披露，文件可在此鏈接查看。此外，內部人士 James William Burns 於 12 月 30 日出售了 2932 股該公司的股票。股票以平均價格 27.09 美元出售，總交易額為 79427.88 美元。交易完成後，該內部人士直接持有 31718 股公司股票，價值 859240.62 美元。此交易代表其持股比例減少了 8.46%。該銷售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士共出售了價值 901977 美元的 33303 股公司股票。公司內部人士持有公司股票的 4.30%。</p>
</div><h2>Institutional Trading of Agios Pharmaceuticals</h2>
<div class="lb-trans"><h2>Agios 製藥的機構交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of the stock. AlphaCentric Advisors LLC purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter worth $358,000. New York State Common Retirement Fund raised its stake in Agios Pharmaceuticals by 3.9% during the fourth quarter. New York State Common Retirement Fund now owns 51,707 shares of the biopharmaceutical company's stock worth $1,407,000 after purchasing an additional 1,917 shares during the period. Campbell &amp; CO Investment Adviser LLC purchased a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at approximately $224,000. Knott David M Jr acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $490,000. Finally, Alps Advisors Inc. lifted its holdings in Agios Pharmaceuticals by 73.8% in the fourth quarter. Alps Advisors Inc. now owns 47,881 shares of the biopharmaceutical company's stock valued at $1,303,000 after acquiring an additional 20,327 shares during the last quarter.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近修改了對該股票的持有。AlphaCentric Advisors LLC 在第四季度購買了 Agios 製藥的新頭寸，價值 358,000 美元。紐約州共同退休基金在第四季度將其在 Agios 製藥的股份增加了 3.9%。紐約州共同退休基金現在持有 51707 股生物製藥公司的股票，價值 1407000 美元，此前在該期間內又購買了 1917 股。Campbell &amp; CO 投資顧問 LLC 在第四季度購買了 Agios 製藥的新股份，價值約 224,000 美元。Knott David M Jr 在第四季度獲得了 Agios 製藥的新頭寸，價值約 490,000 美元。最後，Alps Advisors Inc.在第四季度將其在 Agios 製藥的持股增加了 73.8%。Alps Advisors Inc.現在持有 47881 股生物製藥公司的股票，價值 1303000 美元，此前在上個季度又購買了 20327 股。</p>
</div><h2>About Agios Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Agios 製藥</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.</p>
<div class="lb-trans"><p>Agios 製藥公司成立於 2008 年，是從 Dana-Farber 癌症研究所和 Broad Institute 的研究中分拆出來的生物製藥公司。總部位於馬薩諸塞州劍橋，Agios 專注於理解和針對細胞代謝，以開發用於癌症和罕見遺傳疾病的新療法。該公司的科學平台整合了基因組發現、代謝分析和精準醫學方法，以識別和推進能夠糾正或利用代謝功能障礙的小分子候選藥物。</p>
</div><p>Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.</p>
<div class="lb-trans"><p>Agios 的主要產品是針對特定癌症突變的 IDH（異檸檬酸脱氫酶）抑制劑。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Agios Pharmaceuticals</li>
<li>USAU: The U.S. Gold-Copper Story Investors Can’t Ignore.</li>
<li>The DoD just got a new drone supplier</li>
<li>Think You Missed Silver? You’re Wrong. Here’s Why.</li>
<li>When to buy gold (mathematically)</li>
<li>Trump’s AI Secret: 100X Faster Than Nvidia</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Agios Pharmaceuticals</li>
<li>USAU：投資者無法忽視的美國黃金 - 銅故事。</li>
<li>國防部剛剛獲得了一家新的無人機供應商</li>
<li>認為你錯過了白銀？你錯了。原因在這裏。</li>
<li>何時購買黃金（從數學角度）</li>
<li>特朗普的人工智能秘密：比 Nvidia 快 100 倍</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdJTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=AGIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Agios Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Agios Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Agios Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Agios Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Agios Pharmaceuticals 並不在名單上。</p>
</div><p>While Agios Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Agios Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HC Wainwright 對 Agios 製藥（NASDAQ:AGIO）的股票價格發佈了積極的預測